157 related articles for article (PubMed ID: 38282238)
1. Plasma proteomic profiles of UK Biobank participants with multiple sclerosis.
Jacobs BM; Vickaryous N; Giovannoni G; Proitsi P; Waters S; Dobson R
Ann Clin Transl Neurol; 2024 Mar; 11(3):698-709. PubMed ID: 38282238
[TBL] [Abstract][Full Text] [Related]
2. Proteomics and relationship with axonal pathology in multiple sclerosis: 5-year diffusion tensor imaging study.
Jakimovski D; Qureshi F; Ramanathan M; Gehman V; Keshavan A; Leyden K; Dwyer MG; Bergsland N; Weinstock-Guttman B; Zivadinov R
Brain Commun; 2023; 5(3):fcad183. PubMed ID: 37361716
[TBL] [Abstract][Full Text] [Related]
3. Plasma neurofilament light levels show elevation two years prior to diagnosis of amyotrophic lateral sclerosis in the UK Biobank.
Smith EN; Lee J; Prilutsky D; Zicha S; Wang Z; Han S; Zach N
Amyotroph Lateral Scler Frontotemporal Degener; 2024 Feb; 25(1-2):170-176. PubMed ID: 38013452
[TBL] [Abstract][Full Text] [Related]
4. Plasma proteomic biomarkers and the association between poor cardiovascular health and incident dementia: The UK Biobank study.
Beydoun MA; Beydoun HA; Hu YH; Maino Vieytes CA; Noren Hooten N; Song M; Georgescu MF; Fanelli-Kuczmarski MT; Meirelles O; Launer LJ; Evans MK; Zonderman AB
Brain Behav Immun; 2024 Jul; 119():995-1007. PubMed ID: 38710337
[TBL] [Abstract][Full Text] [Related]
5. Serum neurofilament as a predictor of disease worsening and brain and spinal cord atrophy in multiple sclerosis.
Barro C; Benkert P; Disanto G; Tsagkas C; Amann M; Naegelin Y; Leppert D; Gobbi C; Granziera C; Yaldizli Ö; Michalak Z; Wuerfel J; Kappos L; Parmar K; Kuhle J
Brain; 2018 Aug; 141(8):2382-2391. PubMed ID: 29860296
[TBL] [Abstract][Full Text] [Related]
6. Inflammation-related plasma and CSF biomarkers for multiple sclerosis.
Huang J; Khademi M; Fugger L; Lindhe Ö; Novakova L; Axelsson M; Malmeström C; Constantinescu C; Lycke J; Piehl F; Olsson T; Kockum I
Proc Natl Acad Sci U S A; 2020 Jun; 117(23):12952-12960. PubMed ID: 32457139
[TBL] [Abstract][Full Text] [Related]
7. Glial and neuroaxonal biomarkers in a multiple sclerosis (MS) cohort.
Kalatha T; Hatzifilippou E; Arnaoutoglou M; Balogiannis S; Koutsouraki E
Hell J Nucl Med; 2019; 22 Suppl 2():113-121. PubMed ID: 31802051
[TBL] [Abstract][Full Text] [Related]
8. Association of Serum Neurofilament Light Levels With Long-term Brain Atrophy in Patients With a First Multiple Sclerosis Episode.
Plavina T; Singh CM; Sangurdekar D; de Moor C; Engle B; Gafson A; Goyal J; Fisher E; Szak S; Kinkel RP; Sandrock AW; Su R; Kieseier BC; Rudick RA
JAMA Netw Open; 2020 Nov; 3(11):e2016278. PubMed ID: 33151313
[TBL] [Abstract][Full Text] [Related]
9. Novel plasma and brain proteins that are implicated in multiple sclerosis.
Lin X; Yang Y; Gresle M; Cuellar-Partida G; Han X; Stankovich J; ; Simpson-Yap S; Fuh-Ngwa V; Charlesworth J; Burdon KP; Butzkueven H; Taylor BV; Zhou Y
Brain; 2023 Jun; 146(6):2464-2475. PubMed ID: 36346149
[TBL] [Abstract][Full Text] [Related]
10. Serum neurofilament light chain is more strongly associated with T2 lesion volume than with number of T2 lesions in patients with multiple sclerosis.
Wenger KJ; Hoelter MC; Yalachkov Y; Hendrik Schäfer J; Özkan D; Steffen F; Bittner S; Hattingen E; Foerch C; Schaller-Paule MA
Eur J Radiol; 2023 Sep; 166():111019. PubMed ID: 37549559
[TBL] [Abstract][Full Text] [Related]
11. Searching for neurodegeneration in multiple sclerosis at clinical onset: Diagnostic value of biomarkers.
Novakova L; Axelsson M; Malmeström C; Imberg H; Elias O; Zetterberg H; Nerman O; Lycke J
PLoS One; 2018; 13(4):e0194828. PubMed ID: 29614113
[TBL] [Abstract][Full Text] [Related]
12. Large-scale plasma proteomics comparisons through genetics and disease associations.
Eldjarn GH; Ferkingstad E; Lund SH; Helgason H; Magnusson OT; Gunnarsdottir K; Olafsdottir TA; Halldorsson BV; Olason PI; Zink F; Gudjonsson SA; Sveinbjornsson G; Magnusson MI; Helgason A; Oddsson A; Halldorsson GH; Magnusson MK; Saevarsdottir S; Eiriksdottir T; Masson G; Stefansson H; Jonsdottir I; Holm H; Rafnar T; Melsted P; Saemundsdottir J; Norddahl GL; Thorleifsson G; Ulfarsson MO; Gudbjartsson DF; Thorsteinsdottir U; Sulem P; Stefansson K
Nature; 2023 Oct; 622(7982):348-358. PubMed ID: 37794188
[TBL] [Abstract][Full Text] [Related]
13. Early neurofilament light and glial fibrillary acidic protein levels improve predictive models of multiple sclerosis outcomes.
Bose G; Healy BC; Saxena S; Saleh F; Paul A; Barro C; Lokhande HA; Polgar-Turcsanyi M; Anderson M; Glanz BI; Guttmann CRG; Bakshi R; Weiner HL; Chitnis T
Mult Scler Relat Disord; 2023 Jun; 74():104695. PubMed ID: 37060852
[TBL] [Abstract][Full Text] [Related]
14. Albumin and multiple sclerosis: a prospective study from UK Biobank.
Chen K; Li C; Zhao B; Shang H
Front Immunol; 2024; 15():1415160. PubMed ID: 38915402
[TBL] [Abstract][Full Text] [Related]
15. Serum neurofilament light chain correlates with myelin and axonal magnetic resonance imaging markers in multiple sclerosis.
Yik JT; Becquart P; Gill J; Petkau J; Traboulsee A; Carruthers R; Kolind SH; Devonshire V; Sayao AL; Schabas A; Tam R; Moore GRW; Li DKB; Stukas S; Wellington C; Quandt JA; Vavasour IM; Laule C
Mult Scler Relat Disord; 2022 Jan; 57():103366. PubMed ID: 35158472
[TBL] [Abstract][Full Text] [Related]
16. A multimodal approach to assess the validity of atrophied T2-lesion volume as an MRI marker of disease progression in multiple sclerosis.
Tavazzi E; Bergsland N; Kuhle J; Jakimovski D; Ramanathan M; Maceski AM; Tomic D; Hagemeier J; Kropshofer H; Leppert D; Dwyer MG; Weinstock-Guttman B; Benedict RHB; Zivadinov R
J Neurol; 2020 Mar; 267(3):802-811. PubMed ID: 31768628
[TBL] [Abstract][Full Text] [Related]
17. Lower cerebral arterial blood flow is associated with greater serum neurofilament light chain levels in multiple sclerosis patients.
Jakimovski D; Gibney BL; Marr K; Ramasamy DP; Dwyer MG; Bergsland N; Weinstock-Guttman B; Ramanathan M; Zivadinov R
Eur J Neurol; 2022 Aug; 29(8):2299-2308. PubMed ID: 35474598
[TBL] [Abstract][Full Text] [Related]
18. Association of Multi-Domain Factors with Cognition in the UK Biobank Study.
Tan WY; Hargreaves CA; Kandiah N; Hilal S
J Prev Alzheimers Dis; 2024; 11(1):13-21. PubMed ID: 38230713
[TBL] [Abstract][Full Text] [Related]
19. Quantifying the Association between Objectively Measured Physical Activity and Multiple Sclerosis in the UK Biobank.
Meng Q; Cui E; Leroux A; Mowry EM; Lindquist MA; Crainiceanu CM
Med Sci Sports Exerc; 2023 Dec; 55(12):2194-2202. PubMed ID: 37535318
[TBL] [Abstract][Full Text] [Related]
20. Gene-Environment Interactions in Multiple Sclerosis: A UK Biobank Study.
Jacobs BM; Noyce AJ; Bestwick J; Belete D; Giovannoni G; Dobson R
Neurol Neuroimmunol Neuroinflamm; 2021 Jul; 8(4):. PubMed ID: 34049995
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
